Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUSTIN, TEXAS AND DURHAM, N.C., JUNE 10, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIALLY FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3 BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED A PUBLIC OFFERING OF 10,879,376 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE PER SHARE OF $4.00 AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 7,870,624 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.9999 PER PRE-FUNDED WARRANT. THE PRE-FUNDED WARRANTS HAVE AN EXERCISE PRICE OF $0.0001 PER SHARE AND ARE EXERCISABLE IMMEDIATELY. THE AGGREGATE GROSS PROCEEDS TO SHATTUCK FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $75 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY SHATTUCK, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON JUNE 11, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. IN ADDITION, SHATTUCK HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 2,812,500 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

SHATTUCK LABS, INC. ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING

AUSTIN, TEXAS AND DURHAM, N.C., JUNE 09, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIALLY FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3 BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED A PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK OR, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. IN ADDITION, SHATTUCK EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED PUBLIC OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING. ALL OF THE SECURITIES ARE BEING OFFERED BY SHATTUCK.

SHATTUCK LABS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

AUSTIN, TEXAS AND DURHAM, N.C., JUNE 09, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIALLY FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3-BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED IT HAS RECEIVED NOTICES TO EXERCISE TOTALING APPROXIMATELY 50.6 MILLION COMMON STOCK WARRANTS TO DATE, REPRESENTING APPROXIMATELY 96% OF THE WARRANTS ISSUED IN THE COMPANY'S AUGUST 4, 2025 PRIVATE PLACEMENT.

SHATTUCK LABS ANNOUNCES EXERCISE OF OUTSTANDING COMMON STOCK WARRANTS AND PROVIDES FINANCIAL UPDATE

AUSTIN, TX AND DURHAM, NC, JUNE 08, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIAL FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3 BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED DATA FROM ITS PHASE 1 CLINICAL TRIAL OF SL-325, SHATTUCK'S LEAD DR3 BLOCKING ANTIBODY CANDIDATE.

SHATTUCK LABS ANNOUNCES PHASE 1 RESULTS FOR SL-325

AUSTIN, TEXAS AND DURHAM, N.C., JUNE 05, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIALLY FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3-BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT IT WILL HOST AN INVESTOR CALL AND WEBCAST ON MONDAY, JUNE 8, 2026 AT 8:00 A.M. ET TO PRESENT COMPREHENSIVE PHASE 1 CLINICAL DATA FOR SL-325, INCLUDING SAFETY, TOLERABILITY, PHARMACOKINETICS, RECEPTOR OCCUPANCY, PHARMACODYNAMIC AND IMMUNOGENICITY RESULTS AND PROVIDE A PIPELINE UPDATE.

SHATTUCK LABS TO HOST INVESTOR CALL AND WEBCAST ON PHASE 1 CLINICAL DATA OF SL-325, A POTENTIALLY FIRST-IN-CLASS DR3 BLOCKING ANTIBODY, AND PIPELINE UPDATE ON JUNE 8

AUSTIN, TEXAS AND DURHAM, N.C., MAY 07, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIAL FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3 BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026 AND PROVIDED RECENT BUSINESS HIGHLIGHTS.

SHATTUCK LABS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

AUSTIN, TEXAS AND DURHAM, N.C., MARCH 05, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIAL FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3 BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED RECENT BUSINESS HIGHLIGHTS.

SHATTUCK LABS REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

AUSTIN, TX AND DURHAM, NC, FEB. 25, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF POTENTIALLY FIRST-IN-CLASS MONOCLONAL AND BISPECIFIC DR3-BLOCKING ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PRESENT AT AND PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: CONFERENCE DETAILS TD COWEN 46 TH ANNUAL HEALTH CARE CONFERENCE FORMAT: CORPORATE PRESENTATION AND ONE-ON-ONE MEETINGS PRESENTER: TAYLOR SCHREIBER, M.D., PH.D., CHIEF EXECUTIVE OFFICER PRESENTATION DATE: MARCH 2, 2026 TIME: 9:10 AM ET LOCATION: BOSTON, MA WEBCAST LINK: HERE LEERINK PARTNERS 2026 GLOBAL HEALTH CARE CONFERENCE FORMAT: ONE-ON-ONE INVESTOR MEETINGS PARTICIPANT: TAYLOR SCHREIBER, M.D.

SHATTUCK LABS ANNOUNCES PARTICIPATION IN UPCOMING MARCH INVESTOR CONFERENCES

AUSTIN, TX AND DURHAM, NC, FEB. 06, 2026 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER VIRTUAL NOVEL TARGETS IN IMMUNOLOGY SYMPOSIUM, TAKING PLACE FEBRUARY 12-13, 2026.

SHATTUCK LABS ANNOUNCES PARTICIPATION IN UPCOMING PIPER SANDLER VIRTUAL NOVEL TARGETS IN IMMUNOLOGY SYMPOSIUM

AUSTIN, TX AND DURHAM, NC, DEC. 15, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK OR THE COMPANY) (NASDAQ: STTK), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT IT HAS GRANTED INDUCEMENT EQUITY AWARDS ON DECEMBER 10, 2025 (THE GRANT DATE) TO A NEWLY-HIRED NON-EXECUTIVE OFFICER.

Shattuck Labs, Inc.

STTK

Price

Financial Reports

No items found.

Press Releases

Shattuck Labs, Inc.

STTK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

STTK